foxo4-dri peptide senolytic mouse study 2023 The disordered p53 transactivation domain is the target of FOXO4 and the compound FOXO4-DRI: The Senolytic Peptide That

5-Amino-1MQ is produced under controlled manufacturing conditions designed to promote consistency across production lots and reduce variability between batches

In vivo, GMD eliminates senescent cells and downregulates the expression of senescence-associated genes, in a model of whole-body irradiation 34

The two core mechanism papers were retracted in April 2025 (Kawas 2012, PMID 22129598, retraction notice PMID 40312092

High-dose blends support extended studies, multiple experimental replicates, reduced handling variability, and improved reproducibility in advanced laboratory research.

This makes it a logical choice for EDS patients dealing with chronic joint pain, ligamentous laxity, or tendon injuries